{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:42:53Z","timestamp":1790217773861,"version":"4.1.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Asciminib, a first-in-class allosteric inhibitor of BCR::ABL1 kinase activity, is now approved for the treatment of patients with chronic-phase chronic myeloid leukemia who failed 2 lines of therapy or in patients with the T315I mutation. Promising attributes include high specificity and potency against BCR::ABL1, activity against most kinase domain mutations, and potential for combination therapy with ATP-competitive tyrosine kinase inhibitors. Clinicians now have expanded third-line options, which in most cases will involve a choice between asciminib and ponatinib.<\/jats:p>","DOI":"10.1182\/blood.2021014689","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T20:02:56Z","timestamp":1650916976000},"page":"3474-3479","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Asciminib: a new therapeutic option in chronic-phase CML with treatment failure"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-9927","authenticated-orcid":false,"given":"David T.","family":"Yeung","sequence":"first","affiliation":[{"name":"1Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia;"},{"name":"2Adelaide Medical School, University of Adelaide, Adelaide, Australia; and"},{"name":"3Haematology Department, Royal Adelaide Hospital, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-8797","authenticated-orcid":false,"given":"Naranie","family":"Shanmuganathan","sequence":"additional","affiliation":[{"name":"1Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia;"},{"name":"2Adelaide Medical School, University of Adelaide, Adelaide, Australia; and"},{"name":"3Haematology Department, Royal Adelaide Hospital, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"1Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia;"},{"name":"2Adelaide Medical School, University of Adelaide, Adelaide, Australia; and"},{"name":"3Haematology Department, Royal Adelaide Hospital, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2022061615225731900_B1","author":"US Food and Drug Administration"},{"issue":"11","key":"2022061615225731900_B2","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1038\/s41375-021-01436-6","article-title":"HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions","volume":"35","author":"Bruford","year":"2021","journal-title":"Leukemia."},{"issue":"18","key":"2022061615225731900_B3","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem."},{"issue":"7647","key":"2022061615225731900_B4","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature."},{"key":"2022061615225731900_B5","doi-asserted-by":"crossref","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk Res."},{"issue":"11","key":"2022061615225731900_B6","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/jcph.1926","article-title":"Pharmacokinetics of asciminib in individuals with hepatic or renal impairment","volume":"61","author":"Hoch","year":"2021","journal-title":"J Clin Pharmacol."},{"key":"2022061615225731900_B7","author":"Novartis Pharmaceuticals"},{"issue":"24","key":"2022061615225731900_B8","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med."},{"key":"2022061615225731900_B9","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-139677","article-title":"Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: primary efficacy and safety results from a phase 1 trial [abstract]","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood."},{"issue":"21","key":"2022061615225731900_B10","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood."},{"key":"2022061615225731900_B11","article-title":"Efficacy and safety results from Ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after \u22652 prior tyrosine kinase inhibitors: update after 48 weeks [abstract]","volume":"138(suppl 1)","author":"Mauro","year":"2021","journal-title":"Blood."},{"issue":"24","key":"2022061615225731900_B12","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022061615225731900_B13","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"issue":"27","key":"2022061615225731900_B14","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood."},{"issue":"3","key":"2022061615225731900_B15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell."},{"issue":"10","key":"2022061615225731900_B16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med."},{"issue":"20","key":"2022061615225731900_B17","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022061615225731900_B18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol."},{"issue":"2","key":"2022061615225731900_B19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia."},{"issue":"21","key":"2022061615225731900_B20","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood."},{"issue":"19","key":"2022061615225731900_B21","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med."},{"issue":"4","key":"2022061615225731900_B22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood."},{"key":"2022061615225731900_B23","article-title":"Trial in progress: a multicenter, open label, randomized, phase III study of asciminib (80 mg once daily) vs investigator-selected TKI in newly diagnosed adult patients with chronic myeloid leukemia in chronic phase [abstract]","volume":"138(suppl 1)","author":"Cortes","year":"2021","journal-title":"Blood."},{"issue":"4","key":"2022061615225731900_B24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell."},{"issue":"9","key":"2022061615225731900_B25","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1T315I-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am J Cancer Res."},{"issue":"17","key":"2022061615225731900_B26","doi-asserted-by":"crossref","first-page":"13423","DOI":"10.18632\/oncotarget.24393","article-title":"The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in\u00a0vitro.","volume":"9","author":"Eadie","year":"2018","journal-title":"Oncotarget."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/24\/3474\/1902033\/bloodbld2021014689c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/24\/3474\/1902033\/bloodbld2021014689c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T15:23:22Z","timestamp":1655393002000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/24\/3474\/485054\/Asciminib-a-new-therapeutic-option-in-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":26,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,6,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014689","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]}}}